A phase 1/2 study in patients with mild AD is currently ongoing to assess the safety and tolerability of intrathecally administered ASOs with BIIB080, which targets microtubule associated protein tau (MAPT) mRNA and decreases the amount of tau (Table 1). This evidence concerns the gene MAPT and Alzheimer disease.